with post-herpetic

neuralgia April 2010 —

    Revatio Application submitted in the EU for pediatric PAH — February 2010

    Apixaban Application submitted in the EU for prevention of venous thromboembolism — February 2010

    Xalacom Approval in Japan for the treatment of glaucoma January 2010 —

    Prevenar 13 Application submitted in Japan for prevention of invasive pneumococcal — December 2009 Infant disease in infants and young children

    Xiapex Application submitted in the EU for treatment of Dupuytren’s contracture — December 2009

    Toviaz Application submitted in Japan for overactive bladder — September 2009

In December 2010, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending that the European Commission approve Xiapex for the treatment of Dupuytren’s contracture in adult patients with a palpable cord.

  Late-stage clinical trials for additional uses and dosage forms for in-line products:

  PRODUCT INDICATION

  Eraxis/Vfend Combination Aspergillosis fungal infections

Lyrica     Epilepsy monotherapy; central neuropathic pain due to spinal cord injury; peripheral neuropathic pain

Revatio     Pediatric PAH

Sutent     Adjuvant renal cell carcinoma

Torisel     Renal cell carcinoma

  Zithromax/chloroquine Malaria

Set forth below are developments in 2010 with respect to certain Phase 3 trials for Sutent :

• A Phase 3 trial for advanced castration-resistant prostate cancer was discontinued based on an interim analysis, whereby an independent Data Monitoring Committee (DMC) found that the combination of Sutent with prednisone was unlikely to improve overall survival compared to prednisone alone.

• A Phase 3 trial in combination with erlotinib for the treatment of advanced non-small-cell lung cancer was completed and did not meet its primary endpoint.

• The Phase 3 trial for advanced liver cancer was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced liver cancer.

• Two Phase 3 trials for first-line and second-line treatment of metastatic breast cancer were completed and did not meet their primary endpoints.

 New drug candidates in late-stage development in the U.S.:

CANDIDATE     INDICATION

  Apixaban For the prevention and treatment of venous thromboembolism and prevention of stroke in patients with atrial fibrillation, which is being developed in collaboration with Bristol-Myers Squibb

Company (BMS)

  Aprela (Bazedoxifene- A tissue-selective estrogen complex for the treatment of menopausal vasomotor symptoms conjugated estrogens)

  Axitinib Oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptor 1, 2, & 3 for the treatment of advanced renal cell carcinoma

  Bapineuzumab A beta amyloid inhibitor for the treatment of Alzheimer’s disease being developed in collaboration with Janssen Alzheimer Immunotherapy Research & Development, LLC (Janssen AI), a

subsidiary of Johnson &